Advanced searches left 3/3

Multicenter Clinical Trial - BioProject

Summarized by Plex Scholar
Last Updated: 25 January 2022

* If you want to update the article please login/register

Matador,a multicenter clinical trial. Non-metastatic breast cancer patients were randomized between TAC or ddAC

Patients with pT1-3, pN0-3, M0 breast tumors were randomised between adjuvant dose-dense doxorubicin-cyclophosphamide and docetaxel-cyclophosphamide in 2004 and 2012, according to an adjuvant dose-dense doxorubicin-cyclophosphamide and docetaxel-cyclophosphamide. Overall design: The MATADOR study has a total number of patients: 664. Tumor tissue from 604 patients was used for gene expression analysis. In 7 patients, the Library's preparations failed. For one patient's survival data, survival statistics were missing.

Source link: https://www.ncbi.nlm.nih.gov/bioproject/705699

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions